| Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. | |
MedLine Citation:
|
PMID: 6192443 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Increased production of fetal hemoglobin (HbF) was observed in a patient with sickle cell anemia treated with 5-azacytidine. Each of four courses of therapy resulted in a rapid and prolonged increase in the percentage of HbF containing reticulocytes (F reticulocytes) and HbF containing erythrocytes (F cells). The percentage of HbF in peripheral blood rose from 1.8 to 8.9%. The rise in HbF production was accompanied by an increase in peripheral blood hemoglobin concentration from 8 to 12 g/dl and an increase in mean erythrocyte volume. Treatment with 5-azacytidine resulted in hypomethylation of total genomic and a Y-chromosome-specific DNA fragment isolated from both peripheral blood and bone marrow. Of 15 restriction enzyme sites around the gamma-delta-beta-globin gene complex, only 2 became hypomethylated: one 107 bases 5' to the gamma G and the other 107 bases 5' to the gamma A globin genes. |
Authors:
|
S Charache; G Dover; K Smith; C C Talbot; M Moyer; S Boyer |
Related Documents
:
|
2375963 - Screening for hemoglobins s and c in newborn and adult blood with a monoclonal antibody... 6340353 - Modified hemoglobin solution as a resuscitation fluid. 16830083 - Redirection of the hepatic venous flow for the treatment of pulmonary arteriovenous mal... |
Publication Detail:
|
Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Proceedings of the National Academy of Sciences of the United States of America Volume: 80 ISSN: 0027-8424 ISO Abbreviation: Proc. Natl. Acad. Sci. U.S.A. Publication Date: 1983 Aug |
Date Detail:
|
Created Date: 1983-09-09 Completed Date: 1983-09-09 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7505876 Medline TA: Proc Natl Acad Sci U S A Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 4842-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anemia, Sickle Cell / drug therapy*, genetics Azacitidine / therapeutic use* DNA / genetics*, isolation & purification DNA Restriction Enzymes Fetal Hemoglobin / genetics* Genes / drug effects* Globins / genetics* Humans Male Methylation Nucleic Acid Hybridization |
| Grant Support | |
ID/Acronym/Agency:
|
HL027996/HL/NHLBI NIH HHS; HL15026/HL/NHLBI NIH HHS; HL28028/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
320-67-2/Azacitidine; 9004-22-2/Globins; 9007-49-2/DNA; 9034-63-3/Fetal Hemoglobin; EC 3.1.21.-/DNA Restriction Enzymes |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: T-cell hybridoma specific for a cytochrome c peptide: specific antigen binding and interleukin 2 pro...
Next Document: Phenomenon of formation of giant fat-containing cells in human bone marrow cultures induced by human...